Journal of Comprehensive Cancer Research

Editor in Chief: Dr. Mutian Zhang

Welcoming manuscript submissions for Volume 3

  • About Journal
  • Focus & Scope
  • Editor in Chief
  • Editorial Board
  • Articles
  • Submit Manuscript
  • Article Processing Charges

Journal of Comprehensive Cancer Research (JCCR) is a scholarly Open Access journal which provides extensive coverage in all the areas of cancer. The main aim of the journal is to encourage the researchers to publish most complete and reliable source of information on the discoveries and current developments in the field of cancer science as original research, reviews, commentaries, short communications, letter to editors, mini-reviews etc.

The manuscripts submitted to the journal will be sent out for an extensive peer review by the experts in the field of the manuscript and the first decision will be provided to authors approximately within 28 days from the date of submission. Minimum two independent reviewer’s approval and an editor approval is taken into consideration for acceptance or rejection of a manuscript.

Authors are requested to submit their work to Journal of Comprehensive Cancer Research as an attachment to the editorial office at (or) online at submit manuscript

Articles Published in Journal of Comprehensive Cancer Research will be distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Journal of Comprehensive Cancer Research (JCCR) focuses on disseminating the information on all the areas of cancer, especially novel methods, regimens, therapeutic agents and approaches for identifying and intervening the cancers in early stages, along with facts on advancements that took place in the recent past in treating different cancers.


The scope of Journal of Comprehensive Cancer Research is

  • Adenoma
  • Benign tumors
  • Bladder cancer
  • Bone cancer
  • Brain cancer
  • Breast cancer
  • Cancer chemotherapy
  • Cervical cancer
  • Colon cancer
  • Colorectal cancer
  • Esophageal cancer
  • Gastrointestinal cancer
  • Head and neck cancer
  • Kidney cancer
  • Leukemia
  • Liver cancer
  • Lung cancer
  • Melanoma
  • Metastasis
  • Nasal cancer
  • Non-hodgkin lymphoma
  • Oral cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Radiation therapy
  • Thyroid cancer
  • Uterine cancer
  • Vaginal cancer
Mutian Zhang

Mutian Zhang

Chief Medical Physicist
Department of Radiation Oncology
Summa Health Cancer Institute

Dr. Mutian Zhang is Chief Medical Physicist with the Department of Radiation Oncology, Summa Health Cancer Institute in Akron, Ohio. He leads a team that provides medical physics and radiation dosimetry support to radiation treatment. Dr. Zhang received a B.S. degree in Applied Physics from Tsinghua University, China, and a Ph.D. degree in Medical Physics from Columbia University in New York City. He has been working in the fields of radiation oncology, nuclear medicine, and health physics for more than twenty years. He gained invaluable research experience at the Institute if High Energy Physics, Columbia University, and Memorial Sloan-Kettering Cancer Center.Before joining Summa Health, Dr. Zhang was an Associate Professor with the Department of Radiation Oncology, University of Nebraska Medical Center. He was also the director of Radiation Oncology Residency Program.Dr. Zhang is certified by the American Board of Radiology in therapeutic medical physics.

Dr. Zhang has a successfully history of scientific research, education, academic advisory, and editorial work. He has been an investigator in federal-funded research projects, including tumor hypoxia response to mild temperature hyperthermia, animal tumor motion in complicated imaging studies, multi-modality imaging-guided oxygen tension measurements, and targeted radiotherapy for prostate cancer. Dr. Zhang hasauthored and co-authored numerous publications in peer-reviewed scholarly journals. He is actively participating in radiation oncology clinical practice, radiation therapy clinical trials, radiological physics and radiobiology research, and radiation oncology community services.

Research Interests

Radiobiology; Internal Dosimetry; Tumor Hypoxia; Drug Delivery; Medical Imaging; Image-Guided Radiotherapy; Clinical Dosimetry

Editorial Board

Alfio Ferlito, Professor, Department of Otorhinolaryngology-Head and Neck Surgery, University of Udine, Italy

Ben F. Warner, Clinical Associate Professor, Department of General Practice & Dental Public Health, The University of Texas Health Science Center, USA

Chi-Yu Gregory Lee, Professor Emeritus, University of British Columbia, Canada

Hari K. Koul, Professor and Carroll W. Feist Endowed Chair, Department of Biochemistry & Molecular Biology, Associate Director Feist-Weiller Cancer Center(FWCC), Director for Basic & Translational Research-FWCC, Program Leader, Hormone Related Malignancies Program-FWCC, LSU Health Sciences Center, USA

Jose Russo, Professor, Fox Chase Cancer Center, USA

Kaiser Jamil, Dean and Honorary Professor, Centre of Biotechnology and Bioinformatics, Jawaharlal Nehru Institute of Advanced Studies, India

Kamalesh Kumar Sankhala, Chief, Translational and Clinical Research, Sarcoma Oncology Research Center, LLC/Cancer Center of Southern California, USA

Masayoshi Yamaguchi, Adjunct Professor, University of Hawaii Cancer Center, USA

Michael J Gonzalez, Professor, University of Puerto Rico Medical Sciences Campus, School of Public Health, Department of Human Development, Puerto Rico

Pavan Kumar Tandra, Assistant Professor, Division of Oncology & Hematology, University of Nebraska Medical Center, USA

Rayudu Gopalakrishna, Associate Professor, Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, USA

Vivek Verma, Department of Radiation Oncology, Allegheny General Hospital, USA

Wenting Zhang , Department of Pharmaceutical Sciences, University of Nebraska Medical Center, USA

  • In Press
  • Current Issue
  • Archive

Articles in Press (Volume 3, Issue 1)

  • Open Access Commentary

    The Importance of Thinking about and Quantifying Diseases like Cancer and Heart Disease on a “Health-Spectrum” Continuum

    Authored by: Richard M. Fleming and Matthew R. Fleming

    View PDF

  • Open Access Research Article

    Dysregulated Lipid Metabolism and Lipid Accumulation in Colorectal Neoplasms

    Authored by: Munechika Enjoji, Hiroshi Ishihara, Akikazu Hirano, Yusuke Murata, Ryoko Yada, Makoto Nakamuta, Kentaro Imamura, Takashi Hisabe, Kenji Ohe, and Kenshi Yao

    View PDF

  • Open Access Review Article

    Effect of Pattern Recognition Receptor (PRR) Activation on Immune Suppression and Potential Implications for Cancer Treatment

    Authored by: Shanta Bantia, and Nirmal Choradia

    View PDF

Current Issue (Volume 2, Issue 1)

  • Open Access Mini-Review

    Magnetic Resonance Imaging Guidance in High-Dose Rate Prostate Brachytherapy: Will Radiation Dose Delivery Be More Accurate?

    Authored by: Yu Lei and Mutian Zhang

    View PDF View as HTML

  • Open Access Research Article

    Clinical Features, Prognosis, and Outcome of Patients with Pure Squamous Cell Carcinoma of the Prostate

    Authored by: Daniel Brunnhoelzl and Jue Wang

    View PDF View as HTML

  • Open Access Case Report

    Perivascular Epithelioid Cell Tumour of the Uterus: A Case Report and Review of the Literature

    Authored by: Efterpi Tingi, and Khawla Aswad

    View PDF View as HTML

  • Open Access Case Report

    Spinal Cord Glioblastoma Multiforme: A Rare and Fatal Entity – A Case Report

    Authored by: Flavio Ramalho Romero

    View PDF View as HTML

Sbmit Manuscript

We request you to submit the manuscript through submission form below. Note that all the fields marked* are mandatory. Please also include the full abstract that will help the reviewers to rapidly decide if your paper enters their domain of expertise or not. Also, we request you to submit appropriate keywords of the article to help the editors to assign your paper to the correct reviewers. Acknowledgement of the submitted manuscript will be mailed to corresponding author between 24-48 hours. If you feel any difficulty in submitting the manuscript through online submission system, you may email the manuscript directly to our editorial office at:

Author Details

Article Details

(Cover Letter, Manuscript, Figures, Tables, Supplementary Files)
Add More Attachments

Article Processing Charges

All the manuscripts submitted to Onjourn Publishers are assumed to be submitted under the open access publishing model. Being an open access publisher, we do not collect any subscription charges and allow the readers free access to all its articles. The manuscripts submitted to the journal will be peer reviewed similar way as in subscription model under the control of editorial board members. If the article is found to be acceptable for publishing in a particular journal then the author will be issued with an invoice for payment of article publishing charges. These charges are used as offset expenses for peer review management, journal production and online hosting and archiving. The article publishing charges for the articles accepted for publication in Journal of Comprehensive Cancer Research that are to be paid upon acceptance are

Journal Name Fee (GBP)
Journal of Comprehensive Cancer Research 1389